Takeda's $5.2B Ari­ad deal pays off with a la­bel ex­pan­sion in rare form of leukemia

Take­da’s can­cer drug Iclusig scored an ac­cel­er­at­ed ap­proval in com­bi­na­tion with chemother­a­py from the FDA on Tues­day for new­ly-di­ag­nosed adults with Philadel­phia chro­mo­some-pos­i­tive acute lym­phoblas­tic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER